Dublin, Feb. 14, 2017 -- Research and Markets has announced the addition of the "Cholera Forecast for selected Asian Markets 2017-2027" report to their offering.
Cholera is a bacterial disease caused by infection from Vibrio cholerae species (O1, O139), usually spread through contaminated water. Cholera causes severe diarrhoea and dehydration. Left untreated, cholera can be fatal in a matter of hours, even in previously healthy people.
This report provides the current incidence population for Cholera for Selected Asian Markets (Cambodia, Indonesia, Lao PDR, and Vietnam) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms of Cholera have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Risk factors for contracting cholera relate mostly to contaminated water and sanitation. The disease shows marked seasonality in developing nations, and outbreaks can occur during natural disasters (tsunamis) and complex emergencies (generally affecting the water supply / sanitation infrastructure).
This report is built using data and information sourced from the proprietary patient segmentation database. To generate accurate patient population estimates, the database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Key Topics Covered:
1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography
6. Disease Prognosis & Clinical Course
7. Methodology for quantification of patient numbers
8. Top-line estimated incidence for Cholera
9. Cholera in Vietnam
10. Abbreviations used in the report
11. Patient-Based Offering
12. Online Pricing Data and Platforms
13. References
14. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/vh5jzd/cholera_forecast
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs


Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 



